04.16.26 -- The Top 10 Nations Redrawing The Outsourcing Map

Discover the impact that poor assembly and expression can have on downstream purification and formulation and how addressing these challenges at an early stage ensures cost-effective production.

A GMP‑ready cell bank requires controlled stability, sterility, genetic integrity, and complete documentation to ensure consistent, safe biologic production and meet regulatory expectations.

As capacity expands and capabilities mature, CDMOs with global scale and advanced injectable expertise are becoming critical partners for bringing complex sterile drug products to market.

CDMO selection requires evaluating experience, quality standards, and flexibility. Assess technical transfer skills, supply chain security, and collaborative approach for a reliable, long-term project fit.

Successfully mitigate geopolitical risk and maintain supply continuity. Learn how a large-scale manufacturing process was requalified in eight months to secure a clinical-stage biologic program.

True green chemistry minimizes waste and maximizes effectiveness. Catalysis is a key technology for reducing the E-factor and increasing efficiency across industrial and biological synthesis.

Assimilate how AI is transforming the biomanufacturing industry and how partnerships between pharmaceutical companies and academic institutions are poised to set the new standard.

Operational excellence relies on strong quality foundations that sustain speed and flexibility. Rigorous standards reduce risk, accelerate progress, and build the trust needed for lasting success.

A milliliter-scale approach to IVT optimization reveals how controlled feeding, precise pH management, and real-time monitoring can boost mRNA yield and streamline scale-up to larger bioreactor volumes.

As you plan your next stage of scale-up, take a moment to evaluate whether your manufacturing strategy is built around capacity — or around evolving market demand.